Pharmacological inhibition of CCR2 with RS504393 attenuates both cancer-associated adipocyte formation and cisplatin resistance, highlighting the therapeutic potential of targeting the CCL2-CCR2 axis in HNSCC. The gene discussed is CCL2; the disease is cancer.